Exploring new ways to smooth the path toward better participation for patients and other research and healthcare stakeholders.
Issues concerning the drug approval process in India have occurred in clinical studies resulting in a reduced interest from sponsors. The Drug Controller General of India (DCGI) has been working to amend and update it’s policies to stimulate growth in this sector.
Survey uncovers the challenges, myths, and potential useful strategies associated with BYOD adoption.
Insights from Syneos Health’s 2022 Health Trends: Insights for Industry Change Agent.
Following four key study-design steps is crucial to the delivery of a successful cross-border cancer study
Historically, some longstanding challenges have hindered efforts to integrate patient data from EMRs (Electronic Medical Record systems) with EDC (Electronic Data Capture) systems.
Outlining the requirements and benefits of FDA's four expedited drug approval pathways.
Outlining the requirements and benefits of FDA's four expedited drug approval pathways.
Over recent years global drug companies large or small have recognized that one root cause of the high failure rate in their clinical development lies in the selection of right therapeutic targets.
Using a specific trial, the importance of assessing the success of therapy masking is examined.
Using a specific trial, the importance of assessing the success of therapy masking is examined.
Using a specific trial, the importance of assessing the success of therapy masking is examined.
Using a specific trial, the importance of assessing the success of therapy masking is examined.
How one large academic trial adopted a coordinating center model-helping drive early-model RBM gains
Over the years, clinical study management has become more fragmented. There are more organizations participating in a study, each bringing their own experiences, interpretations of requirements including how quality is defined. How is it possible that requirements and quality be interpreted so differently?
Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.
Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.
Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.
Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.
Endpoint adjudication is gaining importance in pharma today, however, no guidance on endpoint adjudication currently exists. The LinkedIn Endpoint Adjudication Community has generated an Events Charter Template to shed light on the subject for those in need of guidance.
Whether we are referring to CSRs or to IPD, the personal information of trial participants needs to be de-identified prior to release. This article will describe the available methods for de-identifying clinical trial data, and the relative strengths and weaknesses of each.
Leveraging approaches in RBQM to enable effective corrective and preventive action processes.
Biologic drugs and non-biologic complex drugs have revolutionized the treatment of many difficult-to-treat diseases including cancer, multiple sclerosis, and chronic iron deficiency.
Good scientific principles and practices are essential for maintaining quality data that patients can benefit from.
A case study of how cardiac safety assessments can be enhanced with Holter Bin.
Survey shows what keeps Ukrainians away from clinical trials
Understanding the roles of eTMF, CTMS, and study startup solutions in the clinical trials process
New regulations offer opportunity for simplification in strategic planning.